{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:28:35Z","timestamp":1774582115389,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00108-024-01711-5","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:02:04Z","timestamp":1715774524000},"page":"617-623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Wie sicher ist die Gentherapie?","How safe is gene therapy?"],"prefix":"10.1007","volume":"65","author":[{"given":"Stefan","family":"Horn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Fehse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"issue":"6","key":"1711_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/jmg.30.6.506","volume":"30","author":"AE Emery","year":"1993","unstructured":"Emery\u00a0AE, Emery\u00a0ML (1993) Edward Meryon (1809\u20131880) and muscular dystrophy. J\u00a0Med Genet 30(6):506\u2013511","journal-title":"J Med Genet"},{"issue":"3","key":"1711_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig\u00a0M, Hoffman\u00a0EP, Bertelson\u00a0CJ et\u00a0al (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50(3):509\u2013517","journal-title":"Cell"},{"issue":"10","key":"1711_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nrm2024","volume":"7","author":"K Davies","year":"2006","unstructured":"Davies\u00a0K, Nowak\u00a0K (2006) Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 7(10):762\u2013773","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"1711_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen\u00a0CL, Salgado\u00a0D, Monges\u00a0S et\u00a0al (2015) The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36(4):395\u2013402","journal-title":"Hum Mutat"},{"issue":"3","key":"1711_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant\u00a0DJ, Bushby\u00a0K, Bann\u00a0CM et\u00a0al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251\u2013267","journal-title":"Lancet Neurol"},{"issue":"7","key":"1711_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt\u00a0E, Thompson\u00a0R, Sejersen\u00a0T et\u00a0al (2020) Life expectancy at birth in Duchenne muscular dystrophy: a\u00a0systematic review and meta-analysis. Eur J Epidemiol 35(7):643\u2013653","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"1711_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell\u00a0JR, Al-Zaidy\u00a0SA, Rodino-Klapac\u00a0LR et\u00a0al (2021) Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther 29(2):464\u2013488","journal-title":"Mol Ther"},{"key":"1711_CR8","doi-asserted-by":"publisher","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng\u00a0J, Zhang\u00a0J, Shi\u00a0K et\u00a0al (2022) Drug development progress in duchenne muscular dystrophy. Front Pharmacol 13:950651","journal-title":"Front Pharmacol"},{"issue":"s2","key":"1711_CR9","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan\u00a0N, Dickson\u00a0G (2021) Gene Therapy for Duchenne Muscular Dystrophy. J\u00a0Neuromuscul Dis 8(s2):S303\u2013S316","journal-title":"J Neuromuscul Dis"},{"key":"1711_CR10","unstructured":"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-topline-results-embark-global-0. Zugegriffen: 31. Januar 2024"},{"key":"1711_CR11","doi-asserted-by":"crossref","unstructured":"Fehse B, Gr\u00fcnewald J, Petri K (2023) Genome-Editing \u2013 Gentherapie 2.0 oder nur eine Wunschvorstellung? In: Fehse B, Schickl H, Bartfeld S, et\u00a0al (eds) Gen- und Zelltherapie 2.023 \u2013 Forschung, klinische Anwendung und Gesellschaft. Springer, Berlin, Heidelberg, S103\u2013120","DOI":"10.1007\/978-3-662-67908-1_7"},{"issue":"13","key":"1711_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek\u00a0A, Wong\u00a0B, Keeler\u00a0A et\u00a0al (2023) Death after High-Dose rAAV9 Gene Therapy in a\u00a0Patient with Duchenne\u2019s Muscular Dystrophy. N\u00a0Engl J Med 389(13):1203\u20131210","journal-title":"N Engl J Med"},{"key":"1711_CR13","unstructured":"https:\/\/cureduchenne.org\/all-news\/nationwide-researchers-announce-restoration-of-full-length-dystrophin-in-humans\/. Zugegriffen: 29. Januar 2024"},{"issue":"3","key":"1711_CR14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1152\/physrev.00046.2017","volume":"98","author":"Y Zhang","year":"2018","unstructured":"Zhang\u00a0Y, Long\u00a0C, Bassel-Duby\u00a0R et\u00a0al (2018) Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing. Physiol Rev 98(3):1205\u20131240","journal-title":"Physiol Rev"},{"key":"1711_CR15","unstructured":"https:\/\/www.mdaconference.org\/abstract-library\/a-collaborative-analysis-by-clinical-trial-sponsors-and-academic-experts-of-anti-transgene-saes-in-studies-of-gene-therapy-for-dmd\/. Zugegriffen: 31. Januar 2024"},{"issue":"24","key":"1711_CR16","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG B\u00f6nnemann","year":"2023","unstructured":"B\u00f6nnemann\u00a0CG, Belluscio\u00a0BA, Braun\u00a0S et\u00a0al (2023) Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy. N\u00a0Engl J Med 388(24):2294\u20132296","journal-title":"N Engl J Med"},{"key":"1711_CR17","unstructured":"https:\/\/www.parentprojectmd.org\/wp-content\/uploads\/2021\/12\/DMD-Study-1001-Update_Letter-to-the-Community.pdf. Zugegriffen: 31. Januar 2024"},{"issue":"3","key":"1711_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JND-221639","volume":"10","author":"A Lek","year":"2023","unstructured":"Lek\u00a0A, Atas\u00a0E, Hesterlee\u00a0SE et\u00a0al (2023) Meeting Report: 2022 Muscular Dystrophy Association Summit on \u2018Safety and Challenges in Gene Transfer Therapy. J\u00a0Neuromuscul Dis 10(3):327\u2013336","journal-title":"J Neuromuscul Dis"},{"key":"1711_CR19","unstructured":"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-open-first-us-sites-phase-3-trial-investigational#:~:text=NEW%20YORK%2C%20NY%2C%20April%2028,Duchenne%20muscular%20dystrophy%20(DMD)). Zugegriffen: 05.\u00a0Februar 2024"},{"key":"1711_CR20","unstructured":"https:\/\/www.fda.gov\/media\/151599\/download. Zugegriffen: 31. Januar 2024"},{"issue":"12","key":"1711_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","volume":"22","author":"PB Shieh","year":"2023","unstructured":"Shieh\u00a0PB, Kuntz\u00a0NL, Dowling\u00a0JJ et\u00a0al (2023) Safety and efficacy of gene replacement therapy for X\u2011linked myotubular myopathy (ASPIRO): a\u00a0multinational, open-label, dose-escalation trial. Lancet Neurol 22(12):1125\u20131139","journal-title":"Lancet Neurol"},{"issue":"17\u201318","key":"1711_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis\u00a0A (2022) Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma. Hum Gene Ther 33(17\u201318):842\u2013844","journal-title":"Hum Gene Ther"},{"issue":"14","key":"1711_CR23","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou\u00a0J, de Pellegars\u00a0A, Porcheret\u00a0F et\u00a0al (2022) Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv 6(14):4266\u20134270","journal-title":"Blood Adv"},{"key":"1711_CR24","unstructured":"https:\/\/www.novartis.com\/news\/media-releases\/novartis-presents-new-data-safety-and-efficacy-zolgensma-including-maintained-and-improved-motor-milestones-older-and-heavier-children-sma. Zugegriffen: 05. M\u00e4rz 2024"},{"key":"1711_CR25","doi-asserted-by":"publisher","first-page":"991832","DOI":"10.3389\/fimmu.2022.991832","volume":"13","author":"X Li","year":"2022","unstructured":"Li\u00a0X, Wei\u00a0X, Lin\u00a0J et\u00a0al (2022) A versatile toolkit for overcoming AAV immunity. Front Immunol 13:991832","journal-title":"Front Immunol"},{"issue":"3","key":"1711_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","volume":"37","author":"M Arjomandnejad","year":"2023","unstructured":"Arjomandnejad\u00a0M, Dasgupta\u00a0I, Flotte\u00a0TR et\u00a0al (2023) Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer. BioDrugs 37(3):311\u2013329","journal-title":"BioDrugs"},{"issue":"1","key":"1711_CR27","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","volume":"11","author":"J Weinmann","year":"2020","unstructured":"Weinmann\u00a0J, Weis\u00a0S, Sippel\u00a0J et\u00a0al (2020) Identification of a\u00a0myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun 11(1):5432","journal-title":"Nat Commun"},{"key":"1711_CR28","doi-asserted-by":"crossref","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A et\u00a0al (2021) Directed evolution of a\u00a0family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184(19):4919\u20134938.e22","DOI":"10.1016\/j.cell.2021.08.028"},{"key":"1711_CR29","unstructured":"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-progress-myoaav-program-and. Zugegriffen: 20. Februar 2024"},{"key":"1711_CR30","unstructured":"https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-reports-additional-preclinical-data-demonstrating-that-its-novel-capsid-aav-slb101-provides-superior-transduction-efficiency-and-enhanced-distribution-to-skeletal-muscle. Zugegriffen: 20. Februar 2024"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01711-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:02:49Z","timestamp":1716998569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01711-5"}},"subtitle":["Zweiter Todesfall nach Therapie der Duchenne-Muskeldystrophie","Second death after Duchenne therapy"],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01711-5","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"10 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Horn und B.\u00a0Fehse geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}